Inhibition of the acetyltransferases p 300 and CBP reveals a targetable function for p 300 in the survival and invasion pathways of prostate cancer cell lines
暂无分享,去创建一个
W. Parson | P. Cole | D. Meyers | J. Bouchal | Z. Culig | H. Erb | S. Oh | F. R. Santer | I. Cavarretta | Philipp P S Höschele | P. P. Höschele | F. Santer
[1] Lin-Feng Chen,et al. Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. , 2010, Cellular signalling.
[2] Ruben Abagyan,et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.
[3] J. D. den Dunnen,et al. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation , 2010, Nucleic acids research.
[4] Z. Culig,et al. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells , 2010, Endocrine-related cancer.
[5] E. Tajkhorshid,et al. Functional Interplay between Acetylation and Methylation of the RelA Subunit of NF-κB , 2010, Molecular and Cellular Biology.
[6] L. Kenner,et al. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. , 2009, Cancer research.
[7] S. Agrawal,et al. Inhibition of Lysine Acetyltransferase KAT3B/p300 Activity by a Naturally Occurring Hydroxynaphthoquinone, Plumbagin* , 2009, The Journal of Biological Chemistry.
[8] C. Takimoto,et al. Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes , 2009, Clinical Cancer Research.
[9] P. Cole,et al. Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. , 2008, Current opinion in structural biology.
[10] Francis J Giles,et al. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. , 2008, Cancer letters.
[11] S. Triezenberg,et al. Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. , 2008, Virology.
[12] Yi Zhang,et al. New Nomenclature for Chromatin-Modifying Enzymes , 2007, Cell.
[13] D. Tindall,et al. Androgen deprivation increases p300 expression in prostate cancer cells. , 2007, Cancer research.
[14] Yun-Jin Jung,et al. Curcumin is an inhibitor of p300 histone acetylatransferase. , 2006, Medicinal chemistry (Shariqah (United Arab Emirates)).
[15] E. Seto,et al. Acetylation and deacetylation of non-histone proteins. , 2005, Gene.
[16] D. Tindall,et al. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. , 2005, Cancer research.
[17] Georg Bartsch,et al. Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.
[18] Stefan Schmidt,et al. Cancer cell line identification by short tandem repeat profiling: power and limitations , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] Georg Bartsch,et al. The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancer , 2004, The Journal of pathology.
[20] E. Kalkhoven,et al. CBP and p300: HATs for different occasions. , 2004, Biochemical pharmacology.
[21] E. Rosen,et al. Acetylation of Androgen Receptor Enhances Coactivator Binding and Promotes Prostate Cancer Cell Growth , 2003, Molecular and Cellular Biology.
[22] Dominique Trudel,et al. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. , 2003, Cancer research.
[23] E. Schwarz,et al. NFκB: A Pivotal Transcription Factor in Prostate Cancer Metastasis to Bone , 2003, Clinical orthopaedics and related research.
[24] D. Tindall,et al. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.
[25] P. Krammer,et al. Tumor Immunology , 2018, Medical Immunology.
[26] B. Aggarwal,et al. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines , 2001, Oncogene.
[27] S. Srinivasula,et al. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells. , 2001, Cancer research.
[28] V. Ogryzko,et al. p300 and p300/cAMP-response Element-binding Protein-associated Factor Acetylate the Androgen Receptor at Sites Governing Hormone-dependent Transactivation* , 2000, The Journal of Biological Chemistry.
[29] G. Koh,et al. Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. , 2000, Biochemical and biophysical research communications.
[30] Carlos Caldas,et al. Mutations truncating the EP300 acetylase in human cancers , 2000, Nature Genetics.
[31] D. Livingston,et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. , 2000, Genes & development.
[32] D. Livingston,et al. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation , 1998, Nature.
[33] M. Gerritsen,et al. CREB-binding protein/p300 are transcriptional coactivators of p65. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[34] K. A. Klein,et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.
[35] R. Fridman,et al. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). , 1995, Cancer research.
[36] R. Rees,et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. , 1994, British Journal of Cancer.
[37] G. Murphy,et al. LNCaP model of human prostatic carcinoma. , 1983, Cancer research.
[38] D. Peeper,et al. Metastasis mechanisms. , 2009, Biochimica et biophysica acta.
[39] A. Baldwin,et al. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. , 2006, Oncogene.
[40] A. Rabson,et al. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? , 2004, Journal of cellular biochemistry.
[41] H. Klocker,et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. , 2003, The American journal of pathology.
[42] C. Sawyers,et al. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. , 2002, Molecular and cellular biology.
[43] C. N. Coleman,et al. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. , 1999, Oncogene.